Tisdag 6 Oktober | 19:36:14 Europe / Stockholm
Est. tid*
2027-05-20 N/A Årsstämma
2027-02-17 08:55 Bokslutskommuniké 2026
2026-11-11 08:00 Kvartalsrapport 2026-Q3
2026-08-19 - Kvartalsrapport 2026-Q2
2026-05-22 - X-dag ordinarie utdelning CINPHA 0.00 SEK
2026-05-21 - Årsstämma
2026-05-13 - Kvartalsrapport 2026-Q1
2026-02-18 - Bokslutskommuniké 2025
2026-01-19 - Extra Bolagsstämma 2026
2025-11-20 - Kvartalsrapport 2025-Q3
2025-08-20 - Kvartalsrapport 2025-Q2
2025-05-23 - X-dag ordinarie utdelning CINPHA 0.00 SEK
2025-05-22 - Årsstämma
2025-05-20 - Kvartalsrapport 2025-Q1
2025-02-20 - Bokslutskommuniké 2024
2024-11-14 - Kvartalsrapport 2024-Q3
2024-08-29 - Kvartalsrapport 2024-Q2
LandSverige
ListaSmall Cap Stockholm
SektorHälsovård
IndustriBioteknik
Cinclus Pharma är ett svenskt läkemedelsbolag i klinisk fas. Bolaget är verksamt inom utveckling av molekyler för behandling av syrarelaterade sjukdomar. Bolagets ledande läkemedelskandidat linaprazan glurate utvecklas för behandling av svår gastroesofageal refluxsjukdom (GERD). Cinclus Pharma grundades år 2014 och har sitt huvudkontor i Stockholm, Sverige.

Analysera bolaget i Börsdata!

All ägardata du vill ha finns i Holdings!

Cinclus Pharma: New scientific article highlights rapid and sustained acid control with linaprazan glurate

2026-10-05 09:15:00

Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company developing next-generation treatments for acid-related diseases, announces the publication of results from two Phase 1-studies of linaprazan glurate in Alimentary Pharmacology & Therapeutics. The data in these studies demonstrates rapid and sustained acid control with close to 100% pH control at the highest dose levels.

“These Phase 1-results show rapid and sustained acid control with linaprazan glurate. The dose-response in pH-control and good tolerability observed in these studies support its continued clinical development for patients with erosive GERD,” says Kajsa Larsson, Chief Medical Officer of Cinclus Pharma.

About the studies
The publication describes two open-label Phase 1 studies in Slovenia. In one study, 73 healthy adults received 25 mg, 50 mg or 75 mg of linaprazan glurate once or twice daily for 14 days. Stomach pH and blood levels of linaprazan glurate and its active metabolite, linaprazan, were measured after the first dose and after repeated doses.

In the second study, 67 healthy adults received a single dose of each tablet formulation in a randomized crossover design. The study compared the bioavailability of the new tablet formulation with that of the tablet formulation used in previous studies and assessed the effect of a high-fat meal on the new formulation. The results showed that the new formulation that was used in the Phase III study provided approximately twice the bioavailability of the previously used formulation.
 
Both studies are registered on ClinicalTrials.gov as NCT05627518 and NCT05742984.
 
Article information
Authors: Kajsa Larsson, Kjell Andersson, Gunilla Huledal, Jouni Junnila, Kristofer Katkits Nilsson, Elham Yektaei, Matjaž Fležar and Peter Unge
Journal: Alimentary Pharmacology & Therapeutics
 
To access the article, please click the following link: http://doi.org/10.1111/apt.70980